API production in India, China's drug (including API and intermediate products) cartel has been broken in the last six months. Perhaps China did not realise that India would revive its pharmaceutical industry in such a big way, so it had built additional capacity with a view to capture the pharmaceutical industry of the world. Now due to high capacity, the supply of APIs in China has increased significantly and the reduction in prices is an obvious outcome. Now that APIs are being produced in large quantities in the country, the falling prices of APIs are indicative of the same. But the government will have to be cautious that the industries that have been re-built due to PLIs, do not fall victims of dumping by China again. The biggest apprehension of the entrepreneurs who have invested under the PLI scheme was about this only. Since China has a large excess capacity, China can again resort to dumping of its APIs in India. The Indian government, while being vigilant, will have to make every possible effort to stop dumping in the field of APIs by China. This applies not only in the case of APIs but also in the field of other chemicals. According to experts of the chemical industry, two Indian companies named United Phosphorus Limited (UPL) and Hindustan Chemical Limited (HCL) have set up plants at a cost of ₹500 crore with the aim of self-sufficiency in ‘Sodium Cyanide’ in the country. But since these plants have been set up, China, European Union, Japan and South Korea has started using their economic muscles to reduce the landed price of Sodium Cyanide, despite increase in their production cost. This is making production by UPL and HCL economically unviable. Director General of Trade Remedies (DGTR) of Ministry of Commerce and Industry, has proposed anti-dumping duty on imports from China and European Union. But the process of getting such relief for the industry is long and tedious, the country needs to create an expert intelligence agency in the field of international trade so that any such situation of unethical trade practice by foreign countries and their businesses, can be dealt with successfully. #activeingredients #api #chineseAPI
Sandeep SadhuKhan’s Post
More Relevant Posts
-
Dear connections, India’s API Dependence: Shifting Gears Towards Self-Reliance 🚀 India imports 70% of its APIs from China, with some essential medicines relying 80-100% on these imports. However, the tide is turning with the government's Production Linked Incentive (PLI) scheme making strides. With 62% of the ₹6,500 crore investment realized, and key projects like Penicillin-G manufacturing set to go live by FY2025, India is moving towards reducing its dependence on China. This shift not only strengthens our pharma supply chain but also enhances cost efficiency and domestic production capabilities. The future of Indian pharma is bright! #Pharma #API #PLIScheme #SelfReliance #SupplyChainManagement #Pharmaceuticals
To view or add a comment, sign in
-
As a recent GTRI study shows India's import dependence on China has increased in the industrial sector. In the pharmaceutical active ingredients also, China's share in India's imports has increased, from 70% in 2019 to 72% in 2022. This is despite India having a PLI scheme solely dedicated to reducing import dependence on APIs. It is not just India, but other countries' dependence on China has increased on APIs despite all efforts at supply chain diversification and China + strategies.
To view or add a comment, sign in
-
It's high time India must ramp up production of API domestically without which we cannot boast as the Pharma hub of the world !. We should become net exporter of API !. The agony here, is the government know this reality, but yet to implement in coordination with the industry. Industry too seems lethargic on this front due to cheaper imports. This dependency must end !. #import #export #pharma #API #China #India
A recent GTRI study shows India's import dependence on China has increased in the industrial sector. My own analysis on active pharmaceutical ingredients shows that China's share in India's imports has increased, from 70% in 2019 to 72% in 2022. This is in spite of India having a PLI scheme solely dedicated to reducing import dependence on APIs. It is not just India, but other countries' dependence on China has increased on APIs despite all efforts at supply chain diversification and China + strategies. Ajay Srivastava
To view or add a comment, sign in
-
🔵 🔴 India takes tiny steps back from its China dependency🔴 🔵 China can win a war without firing a single bullet. It is an exaggeration but a useful one to underline India's dependence on China for a critical product -- medicines. Though India's pharmaceuticals industry is the third largest in the world, India has to import heavy quantities of raw materials, active pharmaceutical ingredients (APIs) and key starting materials 9KSMs), also called bulk drugs, which go into producing medicines. After decades of this China dependency, India is now trying to break free as the government has begun promoting domestic production of raw material with a Production-Linked Incentive (PLI) scheme. Report Credit : The Economics Times Source : https://lnkd.in/d-2P9eQB Team, Rasayano Industries
India takes tiny steps back from its China dependency
economictimes.indiatimes.com
To view or add a comment, sign in
-
India is often hailed as the "Pharmacy of the World," fighting against serious enemies like cancer. However, the Active Pharmaceutical Ingredient (#API) sector, a cornerstone of this industry, faces several formidable challenges like: 1. Stricter Pollution Control Norms 2. Interpretation of The Drug Price Control Order (DPCO) 2013 3. Lack of Financial Incentives or Policies 4. Lack of Mega Bulk Drug Parks 5. Issues in the Fermentation Industry 6. Cheaper Imports from Neighbouring Countries The #APImanufacturing industry yearns for revival. India needs a holistic and conducive ecosystem for API manufacturing. 1. Faster Environmental Clearances 2. Develop Large Clusters with Infrastructural Support 3. Industry-Academia Initiatives 4. Facilitate Alternative Sources of Import There has to be a multifaceted approach that addresses both immediate challenges and long-term sustainability. India can enhance its self-reliance, ensure health security, and reclaim its position as a global leader in API manufacturing. But, only when, policymakers, industry stakeholders, & academic institutions are ready to collaborate. How do you envision the future of India's API industry? #pharmaindustry #bectochem #pharmaequipments
To view or add a comment, sign in
-
Spike in freight rate may hit momentum of pharma exports According to data from the Directorate General of Foreign Trade (DGFT), Madhya Pradesh, the exports of pharmaceutical products from the state stood at Rs 9,737 crore from April 2023 to January 2024. In the last fiscal, total exports of pharmaceutical products from the state was Rs 10,771 crore. #Spikeinfreightrate | #MomentumofPharmaExports | #DirectorateofGeneralofForeignTrade | #PharmaceuticalProducts | #Healthnews Read more:
Spike in freight rate may hit momentum of pharma exports - ET HealthWorld | Pharma
health.economictimes.indiatimes.com
To view or add a comment, sign in
-
IOL Chemicals and Pharmaceuticals Limited Q4 & FY24 income stands at Rs. 511 Crore Here are the salient features of this report : FY24 Financial Highlights · Total income at ₹ 2,162.9 Cr against ₹ 2,242.7 Cr · EBITDA up 3.8% YoY to ₹ 261.6 Cr · Net profit at ₹ 135 Cr against ₹ 140 Cr Q4FY24 Financial Highlights · Total income at ₹ 511 Cr against 596 Cr · EBITDA at ₹ 57.6 Cr against ₹ 104.5 Cr · Net profit at ₹ 28.2 Cr against ₹ 65.3 Cr Operational Highlights Successfully completed the Brazilian Health Regulatory Agency (ANVISA) GMP audit of all the 10 APIs manufacturing Units situated at Barnala, Punjab without any observation. Approval from Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA), China to export “Metformin Hydrochloride” in China Market · Received CEP Certificate for Losartan Potassium issued by EDQM which will enable higher export to European market · Commenced plant for Acetic Anhydride, for captive consumption as well as merchant sale · CARE Rating has reaffirmed to A+ with a stable outlook Varinder Gupta Vikas Gupta For detailed report click on the link below: https://lnkd.in/dj2Qxfpt
To view or add a comment, sign in
-
Indian Pharma Export 8.4 per cent growth in July #Indiapharmaexport #Indiaspharmaceuticalmarket #Indiandrugindustrygrowth #PharmaexportfromIndia #PharmaImport #PharmaceuticalimportsinIndia
Indian Pharma Export 8.4 per cent growth in July
https://thehealthmaster.com
To view or add a comment, sign in
-
Derisking vs, decoupling; global supply chain transformation is an ongoing change in strategic direction for many organizations. For example, US pharmaceutical companies are reducing reliance on China for drug production due to geopolitical conflicts and quality issues. In 2023, the FDA warned about defective China-made syringes. The US raised tariffs in 2024 on Chinese-made syringes and needles from 0% to 50%. The governmental goal was to drive high-quality products. Some have reported higher healthcare costs instead. Shifting away from Chinese-manufactured drugs is challenging. Here are some data points from a recent WSJ article on why changing strategic direction is a long-term outcome: 1) “China produces about 1/3 of the world's antibiotics, making it a significant supplier 2) Chinese drugmaker, WuXi AppTec, is involved in producing about 1/4 of the medications used in the U.S 3) The US has 28% of its facilities manufacturing active pharmaceutical ingredients onshore” What is your view of derisking supply chains in your industry? What are the best practice risk management considerations you recommend? Check out the WSJ article, November 1, 2024, “U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners” #RiskManagement #Trade #SupplyChain #Leaders Longview Leader Corporation
To view or add a comment, sign in
-
Exciting News: India to Restart Penicillin G Manufacturing! India is set to resume manufacturing Penicillin G later this year, marking a significant milestone after a three-decade hiatus. This achievement follows the launch of the Production Linked Incentive (PLI) scheme by the government during the pandemic, aimed at boosting domestic manufacturing during the pandemic. Penicillin G production stopped in India during the 90s after the domestic pharmaceutical industry faced challenges due to cheaper Chinese alternatives flooding the market, leading to the closure of several Indian plants in the past. The production of Penicillin will be restarted by mid-2024 by Hyderabad-based Aurobindo pharma. The PLI scheme has already shown positive results, with a 50% decline in API imports for paracetamol since its launch. This initiative not only strengthens India's pharmaceutical industry but also contributes to the nation's self-reliance in producing essential medicines. With ongoing support from the PLI scheme, the future of API manufacturing in India looks promising. Read the full article written by Anonna Dutt for The Indian Express: https://lnkd.in/gKXFUu-6 #PharmaceuticalIndustry #Manufacturing #SelfReliance #PLIScheme #APIs #PenicillinG
India to restart Penicillin G manufacture: why was it stopped, what changed now
indianexpress.com
To view or add a comment, sign in
Pharmaceutical International Expert in Global supply chain and Emerging market Business developer.
8moAnti dumping duty on steel was introduced to protect Indian industry also . Similarly a lot other products . EXCIPIENTS like MCC , povidone too gets lot resistance from China for Indian players like sigachi etc . India shall not deter trade relation with China just for penicillin.Aurobindo infact had lot agreement with China earlier . Trade war should be amicably settled not by just PLI.